on 24 Jun 2021
Last Applicant/ Owned by
100 New Bridge Street
London
GB
EC4V6JA
Serial Number
77858393 filed on 27th Oct 2009
Registration Number
3859363 registered on 12th Oct 2010
Correspondent Address
Jonathan A. Hyman
Filing Basis
1. intent to use
Disclaimer
NO DATA
[ Product research and development, namely, development of pharmaceuticals and medical devices through preclinical and clinical research in the fields of envenomation, drug overdose, chemical poisoning, venous disease, autoimmune disease, pain and inflammation and cancer therapy ] Surgical apparatus for the treatment of varicose veins; medical syringes; cannula needles, medical tubing for adminisRead More
[ Product research and development, namely, development of pharmaceuticals and medical devices through preclinical and clinical research in the fields of envenomation, drug overdose, chemical poisoning, venous disease, autoimmune disease, pain and inflammation and cancer therapy ]
Surgical apparatus for the treatment of varicose veins; medical syringes; cannula needles, medical tubing for administering drugs; surgical and medical apparatus for producing and administering pharmaceutical foams; surgical or medical apparatus for producing foams for treatment of varicose veins, arterio-venous malformations, oesophageal varices or hydroceles; devices for intravenous administration of pharmaceutical foam; diagnostic devices for grading the severity of venous conditions, snake envenomation and toxic drugs overdose
Pharmaceutical and medicinal preparations and substances, namely, vaccines and vaccine adjuvants, proteins, peptides, sera containing polyclonal antibodies and fragments thereof and polyclonal antibodies and fragments derived therefrom all for use in treating snake envenomation, overdose of toxic substances or sepsis; pharmaceutical preparations and substances for the treatment of thrombosis, [ inflammation, autoimmune disease and sleep disorders; dietetic foods adapted for medical use; ] vaccines; sera; polyclonal antibodies and fragments thereof for in vitro disease testing and for use in treating snake envenomation, overdose of toxic substances or sepsis; pharmaceutical preparations in the form of foams or for use in producing foams for use in sclerotherapy, phlebology, angiology and proctology, for treatment of oesophageal varices, hydroceles, in sterilisation treatment or for treatment of varicose veins or arteriovenous malformations; chemical reagents for medical or veterinary purposes; chemical reagents for therapeutic and diagnostic purposes, namely, for the treatment of and the diagnosis of the presence of toxic substances; pharmaceutical preparations for the treatment of cancer; [ pharmaceutical preparations for the reduction or elimination of circulating cytokines; pharmaceutical preparations for the treatment of neurodegeneration and multiple sclerosis; pharmaceutical preparations for the treatment of pain, including headache and migraine; ] pharmaceutical preparations for promoting the healing of dermal wounds and chronic wounds including ulcers and pressure sores; pharmaceutical and veterinary preparations for the treatment of digoxin, digitalis or other cardio-active glycoside toxicity; pharmaceutical preparations for the treatment of envenomation with snake venom; pharmaceutical preparations for treatment of excess levels of cancer agents; pharmaceutical preparations for the treatment of toxic levels of other pharmaceutical agents; pharmaceutical preparations for the treatment of cytotoxic cancer treatment drug overdose, particularly overdose with methotrexate; [ pharmaceutical preparations for the treatment of sleep apnea; pharmaceutical preparations for the treatment of head lice; ] diagnostic reagents for medical use and for the determination of levels of toxic substances in blood and tissue samples in vitro
[ Chemicals used in science; chemicals for clinical research use; diagnostic reagents and substances for clinical and medical laboratory use; diagnostic reagents and substances for clinical and medical laboratory in vitro research use; polyclonal antibodies and fragments thereof for clinical research use; diagnostic reagents and substances for in vivo clinical and laboratory research use; chemical reagents for scientific research use; chemicals used in science and medicine, namely, adjuvant compositions for use in the manufacture of vaccines and antibodies and antibody fragments for use in diagnostics and assays; cell lines for use in production of whole cell derived vaccines; cell lines for use in research related to virus mediated disease ]
No 77858393
No Service Mark
No PLSS001.007T
Yes
No
No
Yes
No
No
No
No
| Status Date | Action Taken |
|---|---|
| 13th Jul 2023 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| 13th Jul 2023 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| 13th Jul 2023 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| 16th Mar 2023 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| 16th Mar 2023 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| 16th Mar 2023 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| 16th Mar 2023 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| 16th Mar 2023 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| 12th Apr 2022 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| 12th Apr 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
